SceneI: PPHMstockholder meeting, PPHM Corporate Hdqs. Tustin, Cal.
"This is a business meeting," PPHM CEO says, "Let us put aside for the moment all altruistic goals of fighting disease, and focus on our sacred duty as trustees and administrators, that of maximizing stockholder value."
"Partner quickly," someone from PPHM-IHub-Blog blurts. "It's our only chance."
"Go it alone." another says, a demented physician.
"We've already announced our plans," the CEO says. "Regional partnerships. We can't keep it all." He spread his hands expansively. "That said, we really can't take any scenario off the table, especially as we get further and further into favorable results..."
"Partnership. PIII is way too costly," the same blogger blurted again.
"ImClone went it alone all the way to production and distribution, and succeeded," the balding MD muttered, "And had squat compared to PPHM".
"But Bristol-Meyer got ImCL in the end."
"BMY got coldturded. That hurt PPHM and every MAB producer immensely. If there's another ImCL everyone from the FDA to industry will lose it.."
PPHM CEO continued, "Negotiations are now 24-7 instead of all day. We can no longer do our daytime jobs even at night."
"Maximizing shareholder value..." a RB poster shouted, fisting the CEO.
"Let's take a vote," the CEO says. "And for the first time in history, retail stockholdsers' votes will be counted. I confess. I read IHUB on the can... there are laptops in all the executive toilets ...someone on your website...Loof, I think...is having a contest about how much per share you're going to get, and how anxious everyone is to partner..so we know youlong suffering retailer's bottom line...we definitely don't want a lawsuit...but fight if we must. Listen, the banks want in on it now, and might be willing to offer the same amount BP is offering, on more favorable terms. That is, you stockholders could continue owning the entire company."
"Is Bavi really THAT good...?" the blogger asks, voice quavering.
"This has been going on for years," another IHubber says. "We just want to get our money back."
"At this point Bavi is not a cure," the CEO said. "But it looks like we have a shot at having MAB Bavi used with every form of current therapy for solid cancers, including chemo, irraidiation, and surgery...terrific adjunct treatment. That's worth something."
.
